Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06152172 · ClinicalTrials.gov registry record · Phase 1
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
A Phase 1 study of Idiopathic Inflammatory Myopathies and Diffuse Cutaneous Systemic Sclerosis, sponsored by David Porter.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06152172: Active Phase 1 study of Idiopathic Inflammatory Myopathies and Diffuse Cutaneous Systemic Sclerosis, sponsored by David Porter.
NCT06152172 is a Phase 1 study of Idiopathic Inflammatory Myopathies and Diffuse Cutaneous Systemic Sclerosis that is active but no longer recruiting, run by David Porter. The registered enrollment target is 24 participants, below the 205-participant average among 7 other Idiopathic Inflammatory Myopathies trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06152172, a Phase 1 study of Idiopathic Inflammatory Myopathies and Diffuse Cutaneous Systemic Sclerosis, is active but no longer recruiting, sponsored by David Porter.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.
Primary Outcome
Incidence and severity of AEs in Idiopathic inflammatory myopathies
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG KYV-101
Study Locations (1)
Pennsylvania
- Hospital of the Universithy of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What the registry record for NCT06152172 still lists
NCT06152172 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 205-participant average among 7 other Idiopathic Inflammatory Myopathies trials with a reported enrollment target (88% lower).
The record links to 4 conditions, with Idiopathic Inflammatory Myopathies appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06152172 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06152172 about?
NCT06152172 is a clinical study titled "CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101". The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive...
What is the current status of trial NCT06152172?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-08-05. Estimated completion is 2027-02.
What conditions does trial NCT06152172 study?
This clinical trial studies the following conditions: Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, ANCA-Associated Vasculitis, SLE Nephritis.
What interventions are being tested in trial NCT06152172?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KYV-101 (DRUG).
Who is sponsoring clinical trial NCT06152172?
This trial is sponsored by David Porter, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06152172 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Inflammatory Myopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
-
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
RECRUITING · Phase 2
-
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI